Valuation: Botanix Pharmaceuticals Limited

Market Cap 60.15M 42.64M 36.83M 34.61M 31.48M 59.18M 4.08B 406M 159M 2.04B 160M 157M 6.79B P/E 2026 *
-0.94x
P/E 2027 * -1.91x
Enterprise Value 60.15M 42.64M 36.83M 34.61M 31.48M 59.18M 4.08B 406M 159M 2.04B 160M 157M 6.79B EV / Sales 2026 *
1.67x
EV / Sales 2027 * 0.94x
Free-Float
99.78%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Botanix Pharmaceuticals Limited

1 day-4.55%
1 week-8.70%
Current month+10.53%
1 month-16.00%
3 months-22.22%
6 months-68.18%
Current year-84.44%
1 week 0.02
Extreme 0.02
0.02
1 month 0.02
Extreme 0.019
0.03
Current year 0.02
Extreme 0.018
0.15
1 year 0.02
Extreme 0.018
0.17
3 years 0.02
Extreme 0.018
0.54
5 years 0.02
Extreme 0.018
0.54
10 years 0.02
Extreme 0.018
0.54
Manager TitleAgeSince
Chief Executive Officer - 2023-08-23
Director of Finance/CFO - 2024-03-25
President 67 2019-05-19
Director TitleAgeSince
Director/Board Member - 2016-06-30
Chairman 56 2019-02-20
Chairman 67 2019-07-17
Date Insider Type Main position Quantity % Market Cap.
4/24/26 Free

Director

1,666,667 0.0751%
10/8/25 Others

Chairman

8,000,000 0.4372%
10/8/25 Others

Chairman

8,000,000 0.4372%
Change 5-day change 1-year change 3-year change Capi.($)
-4.55%-8.70%-86.00%-88.95% 42.64M
+0.21%+5.65%+61.31%+24.93% 335B
+0.11%-4.91%+23.21%-14.83% 68.61B
-2.00%-4.33%+46.66%+127.90% 11.2B
-1.47%-0.82%-3.44%-2.46% 8.49B
-0.34%+2.22%-13.22%-7.03% 4.84B
+1.45%+3.85%-26.84%+18.44% 4.42B
+0.32%-2.16%+0.82%+45.84% 4.28B
+2.57%+1.51%+13.28%+56.25% 2.81B
-1.59%-2.84%-4.94%-2.50% 2.19B
Average -0.53%-1.02%+1.08%+15.76% 44.2B
Weighted average by Cap. +0.12%+3.38%+50.85%+20.68%

Financials

2026 *2027 *
Net sales 35.95M 25.49M 22.01M 20.68M 18.81M 35.37M 2.44B 242M 94.76M 1.22B 95.69M 93.61M 4.06B 63.8M 45.23M 39.06M 36.71M 33.38M 62.77M 4.32B 430M 168M 2.17B 170M 166M 7.2B
Net income -64.87M -45.99M -39.72M -37.32M -33.94M -63.81M -4.4B -437M -171M -2.2B -173M -169M -7.32B -37.17M -26.35M -22.76M -21.38M -19.45M -36.56M -2.52B -251M -97.97M -1.26B -98.92M -96.78M -4.19B
Net Debt - -
Logo Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).
Employees
11
Date Price Change Volume
26-08-17 A$0.0210 -4.55% 8,552,224
26-08-14 A$0.0220 0.00% 1,174,686
26-08-13 A$0.0220 0.00% 5,306,256
26-08-12 A$0.0220 -4.35% 3,463,577
26-08-11 A$0.0230 0.00% 2,650,801
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0220AUD
Average target price
0.4900AUD
Spread / Average Target
+2,127.27%

Quarterly revenue - Rate of surprise